StevanatoSTVN
About: Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Employees: 5,521
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
9% more capital invested
Capital invested by funds: $1.08B [Q3] → $1.19B (+$103M) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 44
0.5% more ownership
Funds ownership: 109.54% [Q3] → 110.05% (+0.5%) [Q4]
0% more funds holding
Funds holding: 129 [Q3] → 129 (+0) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
71% less call options, than puts
Call options by funds: $15K | Put options by funds: $52K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
UBS John Sourbeer 0% 1-year accuracy 0 / 3 met price target | 8%upside $24 | Neutral Maintained | 7 Mar 2025 |
Financial journalist opinion









